BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced presentations at two upcoming scientific conferences:
•Nanomedicines Alliance Industry Symposium, March 6-7, 2013, Rockville, MD ? BIND will provide an oral presentation entitled “Managing Scale-up Challenges for Nanomedicines” in a session discussing Nanomedicine Chemistry Manufacturing and Controls.
•Nanomedicines Alliance Industry Symposium, March 6-7, 2013, Rockville, MD ? BIND will provide an oral presentation entitled “Managing Scale-up Challenges for Nanomedicines” in a session discussing Nanomedicine Chemistry Manufacturing and Controls.
